COMMUNIQUÉS West-GlobeNewswire

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
14/10/2026
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerated, with benefits [...]
Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026
14/10/2026
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2026 at 9.00 EEST Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026 Orion will publish Interim Report for January–September 2026 [...]
Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
14/10/2026
SPM-2551 demonstrated robust and durable pharmacological activity following a single low-dose administration in preclinical Duchenne muscular dystrophy (DMD) models Data support Sapreme's proprietary SPT platform, [...]
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
14/10/2026
Synmosa to lead regulatory approvals, market access, distribution and sales in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Nxera to supply drug product and receive an [...]
Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development
14/10/2026
LONDON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based drug discovery and development in oncology, fibrosis and fibro-inflammatory diseases, today [...]
seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases
14/10/2026
Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary Se RAS ® technology Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the [...]
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
14/10/2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli ® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for [...]
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
14/10/2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for [...]
Phonak launches Roger On Sphere™: the first AI-powered remote microphone to separate speech from noise in real time
14/10/2026
STÄFA, Switzerland, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Phonak today announced Roger On Sphere™, the world's first remote microphone powered by a deep neural network (DNN) that separates speech from background noise in [...]
Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
13/10/2026
Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026 Previously announced asset sale transactions with PTC and Lilly have closed, generating $163. [...]
Acquisition of Own Shares
13/10/2026
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
13/10/2026
-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled, dose-ranging [...]
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026
13/10/2026
WARSAW, Ind., Oct. 13, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Rani Therapeutics to Participate in the Chardan Healthcare Conference
13/10/2026
SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s [...]
CapsoVision to Present at the 20th Annual LD Micro Main Event
13/10/2026
SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
13/10/2026
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo. No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations [...]
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will [...]
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine [...]
TRexBio Announces Closing of Initial Public Offering
13/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of [...]

Pages